The Company’s first product, iCapture™45, is pending FDA clearance. Several clinical trials will commence in the USA and Israel within a few weeks, in addition to an ongoing clinical trial in India
SPRING Vision, developing a technology for noninvasive, real-time, multispectral retinal imaging for automated diagnostics of ocular and systemic diseases, announces investment by MediPress, a public R&D Life Science limited partnership (TASE: MPRS) that invests in medical R&D companies specializing in digital and advanced technologies.
Noam Allon, CEO of SPRING Vision: “We are proud to be chosen by MediPress, a professional, selective fund, led by highly experienced medical executives. We appreciate this vote of confidence, and I believe that this is an important next step for SPRING Vision.”
According to Prof. Joseph Press, Chairman & CEO of MediPress Health, “SPRING Vision is an example of the companies we wish to invest in – breakthrough technology, products that will impact both clinicians and patients, and a highly experienced management team. We believe that this unique combination is the key to success.”
Also Read: AST SpaceMobile Announces Agreement to Sell Its Investment in NanoAvionics
This investment, added to successful previous investments by several private investors, is part of a $2M round, which will remain open until July 14th. The funds will support the development of future products, clinical trials, internal growth and marketing efforts.
The Company’s first product, iCapture™45, is pending FDA clearance. Several clinical trials will commence in the USA and Israel within a few weeks, in addition to an ongoing clinical trial in India.
Future versions of this product and other products in the pipeline will include new features, with a vast market potential: from early detection of retinal diseases, which can save patients’ eyesight and reduce the number of unnecessary surgical procedures; through tissue oximetry which, for the first time, will refer to the oxygenation level of tissues in various depth levels, rather than oximetry of large blood vessels; and microangiography of capillary blood vessels; to the prediction of systemic diseases, which will be enabled by state-of-the-art AI tools and a self-operated autonomous device, significantly reducing mortality rates and with an immediate positive impact on annual expenses of health organizations.